{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:47:16Z","timestamp":1792018036158,"version":"4.4.0"},"reference-count":16,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the Royal College of Physicians of Edinburgh"],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:p>The period 1940\u201380 in the history of ergot was dominated by two investigators, Arthur Stoll and Albert Hofmann. There was great excitement when their group isolated from ergot preparations the powerful psychotropic agent lysergic acid diethylamide (LSD). It was thought that this substance would help to find the cause of schizophrenia and other psychotic disorders, but it would prove to be a great disappointment and Hofmann would say later, in private, that he regretted having spent so much time on the compound. By contrast, bromocriptine, derived from ergocriptine, would prove a pivotal substance in our knowledge of dopamine receptors in the central nervous system. It is widely used for the suppression of lactation, the treatment of prolactinomas and the management of Parkinson\u2019s disease.<\/jats:p>","DOI":"10.4997\/jrcpe.2010.115","type":"journal-article","created":{"date-parts":[[2010,3,15]],"date-time":"2010-03-15T06:29:24Z","timestamp":1268634564000},"page":"77-80","source":"Crossref","is-referenced-by-count":18,"title":["The history of ergot of rye (Claviceps purpurea) III: 1940\u201380"],"prefix":"10.1177","volume":"40","author":[{"given":"MR","family":"Lee","sequence":"first","affiliation":[{"name":"Emeritus Professor of Clinical Pharmacology and Therapeutics, University of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2010,3,1]]},"reference":[{"key":"bibr1-JRCPE.2010.115","unstructured":"1 Holmstedt B, Liljestrand G, editors. Readings in pharmacology. New York: Raven Press; 1981. p. 209\u201313."},{"key":"bibr2-JRCPE.2010.115","unstructured":"2 Hofmann A. Ergot \u2013 a rich source of pharmacologically active substances. In: Swain T, editor. Plants in the development of modern medicine. Cambridge, MA: Harvard University Press; 1972. p. 236\u201360."},{"key":"bibr3-JRCPE.2010.115","doi-asserted-by":"publisher","DOI":"10.4997\/JRCPE.2009.416"},{"key":"bibr4-JRCPE.2010.115","doi-asserted-by":"publisher","DOI":"10.1002\/hlca.19430260326"},{"key":"bibr5-JRCPE.2010.115","volume-title":"LSD: my problem child","author":"Hofmann A.","year":"1980"},{"key":"bibr6-JRCPE.2010.115","unstructured":"6 Stoll WA. [Lysergic acid diethylamide, a hallucinogen from the ergot group.] Schweiz Arch Neut 1947; 60:279. In German."},{"key":"bibr7-JRCPE.2010.115","unstructured":"7See http:\/\/www.erowid.org\/references\/refs.php for a complete list of LSD research papers."},{"key":"bibr8-JRCPE.2010.115","first-page":"1214","volume":"97","author":"Smart RG","year":"1967","journal-title":"Can Med Assoc J"},{"key":"bibr9-JRCPE.2010.115","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(66)72149-5"},{"key":"bibr10-JRCPE.2010.115","unstructured":"10Obituary: Albert Hofmann. Daily Telegraph; 20 May 2008. Available from: http:\/\/www.telegraph.co.uk\/news\/obituaries\/1912485\/Obituary-Albert-Hofmann-LSD-inventor.html"},{"key":"bibr11-JRCPE.2010.115","doi-asserted-by":"publisher","DOI":"10.1007\/BF02178840"},{"key":"bibr12-JRCPE.2010.115","doi-asserted-by":"publisher","DOI":"10.1002\/hlca.19650480618"},{"key":"bibr13-JRCPE.2010.115","doi-asserted-by":"publisher","DOI":"10.1152\/ajplegacy.1954.179.2.301"},{"key":"bibr14-JRCPE.2010.115","unstructured":"14 Fl\u00fcckiger E. The pharmacology of bromocriptine. In: Bayliss RIS, Turner P, Maclay WP, editors. Pharmacological and clinical aspects of bromocriptine (Parlodel). Tunbridge Wells: MCS Consultants; 1976. p. 12\u201326."},{"key":"bibr15-JRCPE.2010.115","volume-title":"Trait\u00e9 philosophique et exp\u00e9rimental de mati\u00e8re m\u00e9dicale et de th\u00e9rapeutique","author":"Giacomini GA.","year":"1839"},{"key":"bibr16-JRCPE.2010.115","unstructured":"16 Joint Formulary Committee. British National Formulary. 57 ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2008. p. 410\u20132."}],"container-title":["Journal of the Royal College of Physicians of Edinburgh"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.4997\/JRCPE.2010.115","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.4997\/JRCPE.2010.115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:23:08Z","timestamp":1777616588000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.4997\/JRCPE.2010.115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["10.4997\/JRCPE.2010.115"],"URL":"https:\/\/doi.org\/10.4997\/jrcpe.2010.115","relation":{},"ISSN":["1478-2715","2042-8189"],"issn-type":[{"value":"1478-2715","type":"print"},{"value":"2042-8189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}